• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews. Urology >Targeted therapies in bladder cancer: an overview of in vivo research.
【24h】

Targeted therapies in bladder cancer: an overview of in vivo research.

机译：膀胱癌的靶向疗法：体内研究概述。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Survival of patients with muscle-invasive bladder cancer is poor and new therapies are needed. Currently, none of the targeted agents that are approved for cancer therapy have been approved for the treatment of bladder cancer and the few clinical trials that have been performed had limited success, often owing to a lack of efficacy and toxic effects. However, many other novel targeted agents have been investigated in animal models of bladder cancer. EGFR, FGFR-3, VEGF, mTOR, STAT3, the androgen receptor and CD24 are molecular targets that could be efficiently inhibited, resulting in reduced tumour growth, and that have been investigated in multiple independent studies. Several other targets, for example COX-2, IL-12, Bcl-xL, livin and choline kinase α, have also been observed to inhibit tumour growth, but these findings have not been replicated to date. Limitations of several studies include the use of cell lines with mutations downstream of the target, providing resistance to the tested therapy. Furthermore, certain technologies, such as interfering RNAs, although effective in vitro, are not yet ready for clinical applications. Further preclinical research is needed to discover and evaluate other possible targets, but several validated targets are now available to be studied in clinical trials.
机译：肌肉浸润性膀胱癌患者的生存很差，需要新的疗法。当前，没有任何一种被批准用于癌症治疗的靶向药物已被批准用于治疗膀胱癌，并且由于缺乏疗效和毒性作用，已经进行的少数临床试验取得了有限的成功。但是，已经在膀胱癌的动物模型中研究了许多其他新型靶向药物。 EGFR，FGFR-3，VEGF，mTOR，STAT3，雄激素受体和CD24是可被有效抑制，导致肿瘤生长降低的分子靶标，并且已在多项独立研究中进行了研究。还观察到其他几种靶标，例如COX-2，IL-12，Bcl-xL，livin和胆碱激酶α，可以抑制肿瘤的生长，但是这些发现迄今尚未被复制。几项研究的局限性包括使用在靶标下游具有突变的细胞系，从而对测试疗法产生抵抗力。此外，某些技术，例如干扰RNA，尽管在体外有效，但尚未准备好用于临床。需要进行进一步的临床前研究以发现和评估其他可能的靶标，但是现在可以在临床试验中研究几种经过验证的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号